USFDA accepts sBLA of TIVDAK for priority review for patients with metastatic cervical cancer

Submission based on positive results from global phase 3 study demonstrating overall survival benefit of TIVDAK over chemotherapy

European Commission approves Pfizer’s Talzenna in combination with Xtandi for treatment of metastatic castration-resistant prostate cancer

TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union

Arco Lab acquires an additional 25% stake in Neviton at Rs. 9.22 Cr

Arco Lab now holds a 50% stake in Neviton

Menarini Group and Insilico Medicine ink agreement for Novel KAT6 inhibitor for treatment of breast cancer

This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.

Jiangsu Vcare files NDA for Vicagrel Capsules with USFDA

Supriya Lifesciences received GMP certification from ANVISA Brazil

The clearance of this audit marks the successful registration of 8 APIs with CADIFA

Healthcare Triangle completes US$2 million private placement debt offering

The company received gross proceeds of approximately US$1.7 million and net proceeds,

Palatin completes sale of Vyleesi to Cosette Pharmaceuticals for up to $171 mn

Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)

Adani and Sirius form JV to digitally transform India's digital economy

Sirius JV will be owned 51% by Sirius and 49% by Adani

Karkions Healthcare bags DSCI Excellence Award 2023

Karkinos Healthcare has demonstrated exceptional dedication to privacy, setting a commendable example for businesses navigating the complexities of the digital landscape